Delcath Systems announced that the FDA approved Hepzato KIT as a liver-directed treatment for adult patients with metastatic uveal melanoma, or mUM, with unresectable hepatic metastases affecting less than 50% of the liver and no extrahepatic disease, or extrahepatic disease limited to the bone, lymph nodes, subcutaneous tissues, or lung that is amenable to resection or radiation.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on DCTH:
- Delcath Systems (NASDAQ:DCTH) Skyrockets on FDA Approval for Hepzato Liver Therapy
- Delcath Systems announces FDA approval of HEPZATO KIT in mUM
- Delcath Systems reports Q2 EPS (58c), consensus (60c)
- Delcath Systems Reports Second Quarter 2023 Results and Provides Business Update
- Delcath Systems names Vojislav Vukovic as Chief Medical Officer